CD4 and cholangiocarcinoma: We focus on the importance of searching for promising biomarkers in peripheral blood samples, like exosomes, interleukins, and CD4+/CD8+ ratio, from patients who have received immunotherapy for CCA, as well as on the correlation between gene mutations and the response to ICIs.